<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080493</url>
  </required_header>
  <id_info>
    <org_study_id>987072</org_study_id>
    <nct_id>NCT03080493</nct_id>
  </id_info>
  <brief_title>Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&amp;E Procedure: a Randomized Controlled Trial</brief_title>
  <acronym>GABA</acronym>
  <official_title>Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&amp;E Procedure: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women having abortion procedures between 15 weeks 0 days and 23 weeks 6 days gestational age
      on the day of their procedure commonly have dilators placed in their cervix overnight before
      the abortion procedure. The dilators are put in during a pelvic exam in the clinic and after
      women go home they expand slowly overnight to open the cervix before the abortion procedure
      the next day. This can be a painful experience and health care providers often give women
      different kinds of pain medicine to help them.

      The investigators are interested in whether a medicine called gabapentin, which is a
      non-narcotic medicine, could help. Gabapentin is approved by the U.S. Food and Drug
      Administration (FDA) for prevention of seizures and for treating nerve pain and doctors are
      also using it to decrease pain for people having surgical procedures.

      The main goals of our study are to learn about:

        1. Women's pain experience with dilators in their cervix overnight before the abortion
           procedure

        2. How well gabapentin works to decrease women's pain while they have the dilators in their
           cervix

      Women who enroll in the study will get a dose of either gabapentin or placebo (a pill with no
      medicine in it) before their dilators are placed in the clinic. The medication they get
      (gabapentin or placebo) will be chosen by chance, like flipping a coin. Neither the women in
      the study nor the doctors giving them the medication will know which medication they receive
      so the investigators can learn about their pain without being influenced by knowing which
      medication they take. Doctors will be able to find out which medication women got if there is
      an emergency or if it changes their medical care.

      The investigators will communicate with women in real time overnight by text messaging to see
      how much pain they are having in the moment and how much pain medicine they are taking.

      The investigators hypothesize that women who receive gabapentin will have a smaller increase
      in their pain with the dilators than women who receive placebo (a pill with no medicine in
      it).

      The investigators' findings will help doctors understand women's pain experience with
      dilators better and possibly provide a new way of treating pain with gabapentin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have planned a double-blind randomized controlled trial of repeated doses
      of gabapentin compared to placebo for pain management during the time after dilator insertion
      and prior to D&amp;E the subsequent day.

        -  Participants will receive gabapentin 600 mg or placebo prior to dilator insertion

        -  Pain scores will be measured via numeric rating scale (NRS) at baseline and 5 minutes
           after last dilator insertion while the participant is in clinic

        -  Additional pain scores, side effects (specifically dizziness and sedation), and
           additional analgesic use will be obtained by text message while the patient is home at 2
           hours, 4 hours, and 8 hours after time of dilator insertion

        -  Subjects will take a second dose of study drug (either gabapentin 600 mg or placebo,
           concordant with their initial medication) at 8 hours after their first dose

        -  Final pain score, side effect, and analgesic use assessment will occur upon presentation
           to the pre-operative are for D&amp;E the subsequent day

      There will be no change in standard insertion of osmotic dilators (hygroscopic dilators only
      with Lidocaine 20mL cervical anesthesia), or provision of home analgesic medications
      (ibuprofen and acetaminophen with codeine in our practice).

      The investigators hypothesize that women who receive gabapentin will report a smaller
      increase in pain from baseline at 8 hours after dilator placement compared to women receiving
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Actual">November 5, 2018</completion_date>
  <primary_completion_date type="Actual">November 5, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized placebo controlled trial, stratified block randomization based on prior vaginal parity (vaginal parity - yes or no). Goal of even distribution of prior vaginal parity between gabapentin and placebo groups as may impact osmotic dilator pain experience</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in NRS Pain Score at 8 Hours After Dilator Insertion</measure>
    <time_frame>8 hours after insertion of last osmotic dilator</time_frame>
    <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in NRS Pain Score at 5 Minutes After Last Dilator Insertion</measure>
    <time_frame>5 minutes after insertion of last osmotic dilator</time_frame>
    <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person before subject leaves clinic appointment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in NRS Pain Score at 2 Hours After Dilator Insertion</measure>
    <time_frame>2 hours after insertion of last osmotic dilator</time_frame>
    <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in NRS Pain Score at 4 Hours After Dilator Insertion</measure>
    <time_frame>4 hours after insertion of last osmotic dilator</time_frame>
    <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in NRS Pain Score at Time of Presentation for D&amp;E Procedure (Day Following Dilator Insertion)</measure>
    <time_frame>Time of presentation for D&amp;E (day after dilator insertion)</time_frame>
    <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person upon presentation for D&amp;E procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Using Narcotic Pain Medication (Acetaminophen/Codeine)</measure>
    <time_frame>Collected between each subject contact (2 hours, 4 hours, 8 hours after dilator insertion and at time of presentation for D&amp;E procedure)</time_frame>
    <description>Subject account of how many used acetaminophen/codeine (standard medications given for supplement NSAID as needed after dilator insertion)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Abortion, Induced</condition>
  <condition>Cervical Preparation</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin 600mg</intervention_name>
    <description>Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Packaged identical to gabapentin dosing</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <other_name>Carboxymethyl cellulose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen/codeine and ibuprofen</intervention_name>
    <description>Over the counter analgesic medications</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <other_name>Tylenol-Codeine No. 3</other_name>
    <other_name>Advil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  15 weeks 0 days gestational age - 23 weeks 5 days gestational age at time of dilator
             insertion

          -  Able to read and write in English

          -  Active cell phone with text messaging capability

          -  Ride home from dilator insertion clinic appointment

        Exclusion Criteria:

          -  Current use of gabapentin or pregabalin

          -  Allergy to gabapentin, acetaminophen, codeine, or ibuprofen

          -  Self reported renal disease (severe impaired renal function)

          -  Self reported current or chronic narcotic use (typical daily use)

          -  Women with any issue that, in the opinion of the investigator, would interfere with
             study participation or generating accurate study data
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha Schimmoeller, MD, MPH, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell Creinin, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Health System</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yan PZ, Butler PM, Kurowski D, Perloff MD. Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. Clin J Pain. 2014 Jul;30(7):613-29. doi: 10.1097/AJP.0000000000000014. Review.</citation>
    <PMID>24281281</PMID>
  </reference>
  <reference>
    <citation>Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia. 2002 May;57(5):451-62. Review.</citation>
    <PMID>11966555</PMID>
  </reference>
  <reference>
    <citation>Mercier RJ, Liberty A. Intrauterine lidocaine for pain control during laminaria insertion: a randomized controlled trial. Contraception. 2014 Dec;90(6):594-600. doi: 10.1016/j.contraception.2014.07.008. Epub 2014 Jul 23.</citation>
    <PMID>25139724</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <results_first_submitted>March 6, 2020</results_first_submitted>
  <results_first_submitted_qc>March 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2020</results_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abortion</keyword>
  <keyword>Osmotic dilators</keyword>
  <keyword>Gabapentin</keyword>
  <keyword>Text message</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Codeine</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03080493/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gabapentin</title>
          <description>Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Gabapentin 600mg: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
        </group>
        <group group_id="P2">
          <title>Placebo Oral Capsule</title>
          <description>Matched placebo
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Placebo oral capsule: Packaged identical to gabapentin dosing
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not provide NRS pain results</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization error (parity group)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gabapentin</title>
          <description>Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Gabapentin 600mg: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
        </group>
        <group group_id="B2">
          <title>Placebo Oral Capsule</title>
          <description>Matched placebo
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Placebo oral capsule: Packaged identical to gabapentin dosing
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.4" spread="5.6"/>
                    <measurement group_id="B2" value="27.2" spread="6.1"/>
                    <measurement group_id="B3" value="26.2" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Declined</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reasons for abortion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Unwanted pregnancy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fetal anomalies</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Not completed high school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High school or equivalent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some college</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>College or higher</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Declined</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in NRS Pain Score at 8 Hours After Dilator Insertion</title>
        <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.</description>
        <time_frame>8 hours after insertion of last osmotic dilator</time_frame>
        <population>Women who responded with pain scores by text using Numeric Rating Scale</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Gabapentin 600mg: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsule</title>
            <description>Matched placebo
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Placebo oral capsule: Packaged identical to gabapentin dosing
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in NRS Pain Score at 8 Hours After Dilator Insertion</title>
          <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.</description>
          <population>Women who responded with pain scores by text using Numeric Rating Scale</population>
          <units>Numeric rating scale pain score change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-3" upper_limit="8"/>
                    <measurement group_id="O2" value="2.5" lower_limit="-5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in NRS Pain Score at 5 Minutes After Last Dilator Insertion</title>
        <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person before subject leaves clinic appointment.</description>
        <time_frame>5 minutes after insertion of last osmotic dilator</time_frame>
        <population>Women who provided Numeric rating scale pain score</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Gabapentin 600mg: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsule</title>
            <description>Matched placebo
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Placebo oral capsule: Packaged identical to gabapentin dosing
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in NRS Pain Score at 5 Minutes After Last Dilator Insertion</title>
          <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person before subject leaves clinic appointment.</description>
          <population>Women who provided Numeric rating scale pain score</population>
          <units>Numeric rating scale pain score change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="-6" upper_limit="10"/>
                    <measurement group_id="O2" value="2" lower_limit="-5" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in NRS Pain Score at 2 Hours After Dilator Insertion</title>
        <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.</description>
        <time_frame>2 hours after insertion of last osmotic dilator</time_frame>
        <population>Women who responded by text with numeric pain scale score</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Gabapentin 600mg: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsule</title>
            <description>Matched placebo
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Placebo oral capsule: Packaged identical to gabapentin dosing
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in NRS Pain Score at 2 Hours After Dilator Insertion</title>
          <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.</description>
          <population>Women who responded by text with numeric pain scale score</population>
          <units>Numeric rating scale pain score change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="-8" upper_limit="9"/>
                    <measurement group_id="O2" value="4" lower_limit="-2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in NRS Pain Score at 4 Hours After Dilator Insertion</title>
        <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.</description>
        <time_frame>4 hours after insertion of last osmotic dilator</time_frame>
        <population>Women who responded by text with numeric pain scale score</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Gabapentin 600mg: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsule</title>
            <description>Matched placebo
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Placebo oral capsule: Packaged identical to gabapentin dosing
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in NRS Pain Score at 4 Hours After Dilator Insertion</title>
          <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.</description>
          <population>Women who responded by text with numeric pain scale score</population>
          <units>Numeric rating scale pain score change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="-8" upper_limit="9"/>
                    <measurement group_id="O2" value="3.5" lower_limit="-3" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in NRS Pain Score at Time of Presentation for D&amp;E Procedure (Day Following Dilator Insertion)</title>
        <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person upon presentation for D&amp;E procedure.</description>
        <time_frame>Time of presentation for D&amp;E (day after dilator insertion)</time_frame>
        <population>Women who provided numeric pain scale scores</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Gabapentin 600mg: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsule</title>
            <description>Matched placebo
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Placebo oral capsule: Packaged identical to gabapentin dosing
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in NRS Pain Score at Time of Presentation for D&amp;E Procedure (Day Following Dilator Insertion)</title>
          <description>Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person upon presentation for D&amp;E procedure.</description>
          <population>Women who provided numeric pain scale scores</population>
          <units>Numeric rating scale pain score change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-8" upper_limit="7"/>
                    <measurement group_id="O2" value="1" lower_limit="-2" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Using Narcotic Pain Medication (Acetaminophen/Codeine)</title>
        <description>Subject account of how many used acetaminophen/codeine (standard medications given for supplement NSAID as needed after dilator insertion)</description>
        <time_frame>Collected between each subject contact (2 hours, 4 hours, 8 hours after dilator insertion and at time of presentation for D&amp;E procedure)</time_frame>
        <population>Any use of narcotics</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Gabapentin 600mg: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsule</title>
            <description>Matched placebo
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Placebo oral capsule: Packaged identical to gabapentin dosing
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Using Narcotic Pain Medication (Acetaminophen/Codeine)</title>
          <description>Subject account of how many used acetaminophen/codeine (standard medications given for supplement NSAID as needed after dilator insertion)</description>
          <population>Any use of narcotics</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One day (from treatment initiation until procedure the following day</time_frame>
      <desc>Only adverse events collected were specific to the intervention: dizziness and tiredness</desc>
      <group_list>
        <group group_id="E1">
          <title>Gabapentin</title>
          <description>Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Gabapentin 600mg: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
        </group>
        <group group_id="E2">
          <title>Placebo Oral Capsule</title>
          <description>Matched placebo
Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight
Placebo oral capsule: Packaged identical to gabapentin dosing
acetaminophen/codeine and ibuprofen: Over the counter analgesic medications</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tiredness at baseline</sub_title>
                <description>Tiredness</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Tiredness at 5 minutes after dilator placement</sub_title>
                <description>Tiredness</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Tiredness at 2 hours after dilator placement</sub_title>
                <description>Tiredness</description>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="54"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Tiredness at 4 hours after dilator placement</sub_title>
                <description>Tiredness</description>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="54"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tiredness at 8 hours after dilator placement</sub_title>
                <description>Tiredness</description>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="57"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tiredness at 18-24 hours after dilator placment</sub_title>
                <description>Tiredness</description>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="60"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness at baseline</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dizziness at 5 minutes after dilator placement</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="60"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dizzines at 2 hours after dilator placement</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="53"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dizziness at 4 hours after dilator placement</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="55"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dizziness at 8 hours after dilator placement</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dizziness at 18-24 hours after dilator placement</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mitchell Creinin, MD</name_or_title>
      <organization>University of California, Davis</organization>
      <phone>916-734-6670</phone>
      <email>mdcreinin@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

